Securities code: 300529 securities abbreviation: Jafron Biomedical Co.Ltd(300529) Announcement No.: 2022-003 bond Code: 123117 bond abbreviation: Jianfan convertible bond
Jafron Biomedical Co.Ltd(300529)
Announcement on resolutions of the 27th meeting of the 4th board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
The 27th meeting of the 4th board of supervisors of Jafron Biomedical Co.Ltd(300529) (hereinafter referred to as “the company”) was held by means of on-site voting and communication voting in the company’s conference room on January 17, 2022. 3 people should attend this meeting and 3 actually attended. The notice of the meeting was delivered to all supervisors by hand on January 13, 2022. The meeting was presided over by Mr. Peng Xiaohong, chairman of the board of supervisors. The meeting was held in accordance with the relevant provisions of the company law of the people’s Republic of China and the articles of association.
2、 Deliberation at the meeting of the board of supervisors
After careful discussion, the attending supervisors deliberated and voted on the following proposals:
1. The proposal on the company’s 2022 stock option incentive plan (Draft) and its summary was reviewed and adopted
Upon review, the board of supervisors believes that the contents of the stock option incentive plan comply with the provisions of the company law, the securities law, the measures for the administration of equity incentive of listed companies and other relevant laws, regulations and normative documents, as well as the articles of association. The implementation of this incentive plan will help to further improve the company’s governance structure, establish and improve the company’s long-term incentive mechanism, attract and retain excellent talents, enhance the company’s directors, senior managers, middle managers and core backbone personnel’s sense of responsibility and mission for realizing the sustainable and healthy development of the company, and better mobilize the initiative, enthusiasm and creativity of personnel, Safeguard the interests of the company and shareholders and achieve the development planning objectives of the company, without damaging the interests of the company and all shareholders.
For details, please refer to cninfo.com, the gem information disclosure website designated by the CSRC on the same day（ http://www.cn.info.com.cn. ）The 2022 stock option incentive plan (Draft) and its abstract issued.
Voting: 3 in favor, 0 against, 0 abstention and 0 avoidance.
2. The proposal on the management measures for the implementation and assessment of the company’s stock option incentive plan in 2022 was reviewed and adopted
After review, the board of supervisors believes that the company’s measures for the administration of the implementation and assessment of the 2022 stock option incentive plan aims to ensure the smooth implementation of the company’s equity incentive plan, ensure the standardized operation of the equity incentive plan, and comply with the provisions of the company law, the securities law, the measures for the administration of equity incentive of listed companies and other relevant laws, regulations and normative documents, as well as the articles of association, It is conducive to the sustainable development of the company and will not damage the interests of the listed company and all shareholders.
For details, please refer to cninfo.com, the gem information disclosure website designated by the CSRC on the same day（ http://www.cn.info.com.cn. ）Management measures for the implementation and assessment of stock option incentive plan in 2022 issued by the State Council.
Voting: 3 in favor, 0 against, 0 abstention and 0 avoidance.
3. The proposal on verifying the list of incentive objects of the company’s stock option incentive plan in 2022 was reviewed and passed
After examination, the board of supervisors believes that the personnel listed in the list of incentive objects of the company’s stock option incentive plan have the qualifications specified in the company law, the articles of association and other laws, regulations and normative documents, and there is no situation that they have been identified as inappropriate candidates by the stock exchange in the last 12 months; There is no case that the CSRC and its dispatched offices have identified it as an inappropriate candidate within the last 12 months; There are no cases in which the CSRC and its dispatched offices have imposed administrative penalties or taken market entry prohibition measures for major violations of laws and regulations in the last 12 months; There is no circumstance that the company is not allowed to serve as a director or senior manager of the company as stipulated in the company law; There is no case that the company is not allowed to participate in the equity incentive of listed companies according to laws and regulations, meets the incentive object conditions specified in the administrative measures for equity incentive of listed companies, meets the incentive object scope specified in the company’s 2022 stock option incentive plan (Draft) and its abstract, and its subject qualification as the incentive object of the company’s current incentive plan is legal and effective.
The company will publicize the names and positions of incentive objects within the company through the company’s website or other channels before the general meeting of shareholders, and the publicity period shall not be less than 10 days. The board of supervisors will disclose the audit opinions on the incentive list and the explanation of its publicity three to five days before the shareholders’ meeting considers the equity incentive plan.
For details, please refer to cninfo.com, the gem information disclosure website designated by the CSRC on the same day（ http://www.cn.info.com.cn. ）List of incentive objects of 2022 stock option incentive plan issued. Voting: 3 in favor, 0 against, 0 abstention and 0 avoidance.
It is hereby announced.
Jafron Biomedical Co.Ltd(300529) board of supervisors January 17, 2022
